14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AHG vs AHD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AHG Overall Winner
6-Pillar Tally: AHG 5 – 0 AHD (1 Tie)
Matrix Metrics: AHG 6 – 2 AHD
As of Nov 20, 2026, Akso Health Group ADS (AHG) is the stronger overall head-to-head candidate over AHD (AHD) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AHG carries a Unified Composite Score of 38.2/100 (SELL) at $1.26 (N/M Forward P/E, -28.9% operating margin), whereas AHD carries 41.6/100 (SELL) at $21.81 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While AHD currently prints a higher short-term Unified Composite Score (41.6/100 SELL vs. AHG 38.2/100 SELL), AHG captures the overall institutional head-to-head verdict (6–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-28.9% vs. N/A operating margin) and revenue trajectory (-12.9% vs. N/A YoY).
Defensive Composite Rating Caution: Although AHG compares more favorably head-to-head, both AHG (38.2/100 SELL) and AHD (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: AHG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 49.6); meanwhile AHD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 13.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AHG vs AHD. Trailing 12-month operating profitability (AHG -28.9% vs AHD N/A) and valuation multiples (AHG N/M vs AHD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Distribution value chain with $1.1B market capitalization and -28.9% operating margin.
OpEx & R&D Reinvestment28.8% of Rev ($4.0M)
90D Engineering Disclosures0 Published
AHD Moat ProfileCyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AHG vs AHD Key Questions & Quantitative Answers
As of Nov 20, 2026, Akso Health Group ADS (AHG) is the stronger overall head-to-head candidate over AHD (AHD) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AHG carries a Unified Composite Score of 38.2/100 (SELL) at $1.26 (N/M Forward P/E, -28.9% operating margin), whereas AHD carries 41.6/100 (SELL) at $21.81 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While AHD currently prints a higher short-term Unified Composite Score (41.6/100 SELL vs. AHG 38.2/100 SELL), AHG captures the overall institutional head-to-head verdict (6–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-28.9% vs. N/A operating margin) and revenue trajectory (-12.9% vs. N/A YoY). Defensive Composite Rating Caution: Although AHG compares more favorably head-to-head, both AHG (38.2/100 SELL) and AHD (41.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: AHG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 49.6); meanwhile AHD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 13.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AHG leads the Growth & Scale pillar: AHG posts -12.9% YoY revenue growth and +0.0% YoY earnings growth on $14M TTM revenue (-0.1% gross margin, -28.9% operating margin), compared with AHD at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, AHG generates $14M in USD-normalized revenue versus N/A for AHD. In operating R&D and SG&A reinvestment, AHG deploys 28.8% of Rev ($4.0M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AHD.
AHG screens cheaper on headline valuation multiples. AHG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 79.3x EV/Revenue (-11.8% EBITDA margin), whereas AHD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHG (-9.8% ROE) versus AHD (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, AHG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.38β · 101% Vol realized risk). By comparison, AHD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.58β · 26% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.